Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Do you offer adjuvant durvalumab for stage I small cell lung cancer following SBRT or surgery?
Extrapolating from the Adriatic trial.
Related Questions
Is there increased risk with lung SBRT in a patient who has a mild asymptomatic pneumothorax in the field after CT-guided needle biopsy?
How do you treat Stage IIIC T4N3 NSCLC?
How would you approach an in-field recurrence after lung SBRT for a T1 NSCLC in a patient with poor underlying lung function?
Would you hold CGRP (calcitonin gene-related peptide) monoclonal antibodies such as Eptinezumab-jjmr (Vyepti) before, during, or after lung SBRT?
How do you approach a patient with stage IIA non-small cell lung cancer who received SBRT?
How do you construct your target volumes for superior sulcus tumors?
What is your planning approach for SBRT when the tumor abuts the great vessels such as aortic arch or SVC?
In ES-SCLC presenting with extensive brain metastases, how do you time whole brain radiation after the first cycle of chemotherapy has already been delivered?
How do you counsel patients with Stage IIIA EGFR+ lung cancer regarding treatment intent with concurrent chemoRT + consolidative systemic therapy?
What constraints do you use for the BID small cell lung cancer regimen?